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DECITABINE-LOADED NANOGEL TREATMENT
TO REVERSE CANCER DRUG RESISTANCE
SAMANTHA A. CRAMER
ABSTRACT
Cancers in which epigenetic changes, such as hypermethylation of DNA, lead to
drug resistance cause the cancer to become unresponsive to existing chemotherapeutic
treatments. The epigenetic drug – 5-aza-2’-deoxycytidine (decitabine, DAC) – is a potent
hypomethylating agent, but its effect is transient due to its instability. Previous studies
have shown that loading DAC into nanogel significantly enhances its antiproliferative
effect (compared to DAC in solution) in drug-resistant breast cancer cells (MCF-7/ADR).
Further, the previous studies demonstrated changes in the membrane lipid profile of
resistant cells following treatment with DAC either as solution or in nanogels. The
objective of the present study was to compare the stability of DAC as solution and DAC
encapsulated in nanogel, determine the effect of duration of DAC and DAC-nanogel
pretreatment on the antiproliferative activity of subsequent chemotherapeutic agent
addition, and to visualize and quantify the effect of DAC and DAC-nanogel pretreatment
on uptake of poly dl-lactide co-glycolide (PLGA)-based nanoparticle in MCF-7/ADR
cells. An increase in the stability of DAC when encapsulated in nanogel could be a
mechanism contributing to the sustained effect of DAC. DAC-nanogel’s sustained effect
and its effectiveness at altering the membrane lipid profile to reduce resistance could
cause a longer DAC-nanogel pretreatment time to increase the antiproliferative effect of
subsequent chemotherapeutic agent addition. Additionally, the membrane lipid profile
altering effects of DAC and DAC-nanogel could cause DAC and DAC-nanogel
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pretreatment to increase uptake of nanoparticles in MCF-7/ADR cells. The stability of
DAC was assessed in mouse plasma at physiological conditions using mass spectrometry.
DAC in solution was found to be less stable than DAC in nanogel. The effect of durations
of 3-days and 5-days of DAC-nanogel treatments on the subsequent efficacy of
chemotherapeutic agent, paclitaxel was assessed in MCF-7/ADR cells using a MTS
assay. The DAC-nanogel had a greater effect with a longer duration of pretreatment time
as determined by the dose-response curve, IC50, and IC70. The effect of DAC or DACnanogel pretreatment of a 3-day duration on subsequent uptake of nanoparticles was
visualized with confocal microscopy and the differences in uptake were quantified.
Increase in uptake of nanoparticles was seen in both DAC and DAC-nanogel with DAC
alone having a greater effect. Overall, this study shows that increased DAC stability is a
contributing factor to the increased efficacy and sustained effect of DAC-nanogel, the
effect of DAC-nanogel on subsequent anticancer drug antiproliferative activity is
significantly increased with a longer duration of pretreatment, and DAC and DACnanogel pretreatment cause a greater uptake of subsequent nanoparticle addition than in
cells without any pretreatment.
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CHAPTER I
INTRODUCTION

1.1 Introduction
Once cancer acquires drug resistance, it is difficult to treat with existing
chemotherapeutics (Solyanik 2010). There are certain changes that cause cancer cells to
become drug-resistant and exhibit characteristics that do not appear in drug-sensitive
cancer cells. One of these characteristics is reduced drug transport into resistant cells due
to changes in the membrane lipid composition leading to greater membrane rigidity than
that of sensitive cell membrane (Peetla et al. 2010). Another characteristic is that drugs
that are transported across the membrane are then trapped in endosomal vesicles so that
they are not available for interaction with intracellular targets, or they are trapped in the
membrane but then effluxed out from the cell via permeability glycoprotein (P-gp) which
is over-expressed in resistant cells. These events, increased rigidity of the cell membrane,
endosomal entrapment, and increased efflux by P-gp lead to impaired drug transport or
endocytosis that affects nanocarrier-mediated drug delivery and cause chemotherapeutic
agents to be less effective (Gottesman 2002; Peetla et al. 2013).
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The acquired drug resistance seen in some cancers is due to epigenetic changes to
the genome (Knappskog and Lønning 2012). These changes affect the expression of the
genes without altering the DNA sequence. 5-aza-2’-deoxycytidine (decitabine [DAC]), a
hypomethylating agent, reactivates silenced genes. DAC treatment achieves
hypomethylation via covalent binding of DNA methyltransferase 1 (DNMT1) (Onda et
al. 2012). This results in a decrease in the amount of DNMT1 available to carry out
methylation. Although the demethylation and reactivation of tumor suppressor genes is
often the primary focus of DAC research, another effect of the hypomethylation is that it
causes the lipid profile of the cell membrane to be altered by means of altered membrane
lipid synthesis (Vijayaraghavalu et al. 2012).
The resistant cells treated with DAC have membrane lipid profiles that resemble
more or less that of a sensitive cell’s lipid profile. When these DAC-treated resistant cells
are then sequentially treated with anti-cancer drug, the anti-cancer drug’s efficacy is
enhanced (Vijayaraghavalu et al. 2012). The benefit of using DAC in this manner – as a
pretreatment – is that although in vitro DAC is an effective antiproliferative agent by
itself, in vivo it becomes toxic at higher doses (especially in bone marrow) due to its
DNA-damaging activity and targeting rapidly dividing bone marrow cells, causing
myelosuppression (Hollenbach et al. 2010). DAC has a significantly short half-life (10 –
35 minutes in vivo) because of its rapid clearance rate as it has low affinity for plasma
proteins, and it is also rapidly degraded by cytidine deaminase in the liver (Jabbour et al.
2008).
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The efficacy of pretreatment with DAC could be improved upon by overcoming
some of the factors that have limited its use in clinical trials. Currently, DAC is approved
by the FDA as a monotherapeutic agent to treat hematological cancers (Boumber and Issa
2011). Treatment of solid tumors with DAC has been attempted in clinical trials with
disappointing results (Boumber and Issa 2011). There are several factors that limit the
performance of DAC in solid tumors, as it cannot achieve therapeutic dose because of
short half-life and repeated and high dosing of DAC to maintain therapeutic level at the
tumor site causes myelosuppression and leukopenia (Momparler et al. 1997). Loading
DAC into nanogel has been shown to significantly enhance its antiproliferative effect in
drug-resistant breast cancer cells (MCF-7/ADR) due to prolonged DNMT1 depletion
(Vijayaraghavalu and Labhasetwar 2013). In aqueous solutions and culture media DAC
rapidly degrades due to hydrolytic opening of the 5-azacytosine ring resulting in many
degradation products (Stresemann and Lyko 2008; Rogstad, D. K. et al. 2009). The
sustained effect may be due to the nanogel increasing DAC stability in culture medium.
In addition to a greater efficacy of DAC, nanogel confers other properties useful in
overcoming difficulties associated with using DAC in vivo. Nanogel can potentially
reduce this toxicity because nanogel may not be able to pass through the openings in the
sinusoidal capillaries of bone marrow as freely as drug molecules. DAC-nanogel could
protect DAC from deamination by cytidine deaminase in the liver, spleen, and plasma
(Stresemann and Lyko 2008). Another benefit of nanogel is that DAC’s method of action
is S-phase dependent. Tumor cells have been shown to divide at a slower pace in vivo
versus in vitro. The sustained effect of DAC-nanogel could expose cancer cells at the
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tumor site to DAC for a longer duration so that the DAC can be incorporated into the
DNA when the cancer cells go through S-phase (Brünner et al. 1989; Oloumi et al. 2010).

1.2 Hypothesis
It is hypothesized that DAC is more stable when loaded in nanogel, that this
stability means the duration of DAC-nanogel pretreatment will correlate with its ability to
increase subsequent drug efficacy, and that DAC-nanogel pretreatment will cause a
greater uptake of nanoparticles in drug resistant breast cancer cells (MCF-7/ADR).

1.3 Specific Aims
1. One aim of this research was to test the stability of DAC alone versus DACnanogel by comparison in plasma under physiological conditions over time using high
pressure liquid chromatography (HPLC), UV/VIS, and mass spectroscopy.
2. A second aim was to determine how duration of pretreatment with DAC and
DAC-nanogel affects the anti-proliferative effect of subsequent chemotherapeutic drug
treatment in drug resistant breast cancer cells. MCF-7/ADR cells were treated with DAC
alone, DAC-nanogel, or control, with durations of three or five days. All samples were
then treated with chemotherapeutic agent and dose response curves, IC50s, and IC70s
(concentration of the drug which causes 50% or 70% inhibition of cell growth) were
obtained using MTS assays.
3. A final aim was to assess nanoparticle uptake in MCF-7/ADR cells after
pretreating with DAC, DAC- nanogel, or no pretreatment. Nanoparticles loaded with 6coumarin dye were added to the pretreated cells. The cells were imaged with confocal
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microscopy. The amount of nanoparticle uptake per cell was quantified using the
intensity of the green 6-coumarin dye.

1.4 Significance of Research
The stability of DAC-nanogel versus DAC alone will be helpful information for
planning the specifics of using DAC- nanogel in vivo. Greater stability would mean a
longer retention time in vivo. The stability could be a part of the mechanism of action
accounting for the increased effectiveness.
Additional information on the mechanism that would aid in vivo study set-up is
the effect of the duration of pretreatment with DAC on uptake of subsequent anticancer
drug. Confocal microscopy of dye-loaded nanoparticles will be used to visualize and
quantify differences after pretreatment with DAC and DAC-nanogel on cellular uptake of
the dye-loaded nanoparticles. The resulting images will show the amount of dye-loaded
nanoparticles inside the cells indicating the amount of endocytosis. The principle of
increased uptake from increased endocytosis of dye-loaded nanoparticles could be
expanded in theory to include uptake of drug or drug-loaded nanoparticles.
Taken together, this research could further the case for using DAC-nanogel as a
pretreatment for drug-resistant cancers. It also elucidates on the mechanism of action –
greater stability and increased uptake by the cell membrane – by which the pretreatment
is improving efficacy.
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CHAPTER II
BACKGROUND

2.1 Cancer Drug Resistance and Epigenetics Role
Drug resistance is a major problem in cancer chemotherapeutics and a
multifactorial phenomenon. The resistance may be preexisting within the genetic code of
the cancer cells, or the resistance may be acquired after treatment with chemotherapeutics
(Solyanik 2010). There are mechanisms of resistance that reduce the amount of drug
within the cell via decreased drug influx, drug sequestration in intracellular vesicles, and
increased drug efflux by way of P-glycoprotein (P-gp) (also known as multidrug
resistance [MDR] protein 1) pumps. Other mechanisms change the apoptotic cell
pathways to avoid cell death (Gottesman 2002; Pérez-Tomás 2006). Cancers that acquire
drug resistance may do so through genetic changes to the genome. An example of
acquired resistance through genetics is the mutation of the gene for p53 which causes a
decrease in apoptosis (Knappskog and Lønning 2012).
Epigenetics is a change in the genetic activity without changing the nucleotide
sequence. Mechanisms of epigenetic regulation include DNA methylation, chromatin
remodeling (histone modification), small interfering RNA (siRNA) and micro RNA
6

(miRNA) – mediation (Nakao 2001; Bird 2007; Goldberg et al. 2007). Methylation –
methyl group addition to DNA - is known for its gene silencing effect but can also
regulate imprinting and X-chromosome inactivation. DNA methyltransferase (DNMT) is
the enzyme responsible for methylation in mammal genomes. DNMT adds methyl groups
to clusters of cytosine and guanine near gene promoters (termed CpG islands) or to
histone amino acids, affecting gene expression (Jones and Takai 2001; Jones 2012). The
role of methylation in acquired drug resistance in cancer has been extensively studied.
There is an increase in methylation (hypermethylation) of promoters of several tumor
suppressor genes such as retinoblastoma tumor-suppressor gene (Rb) and breast cancer
type 1 susceptibility protein (BRCA1) (Esteller 2007). Hypomethylation is also seen in
acquired drug resistant in genes that prevent apoptosis and enhance cell survival
(Gopisetty et al. 2006).

2.2 Approaches for Overcoming Resistance
Significant effort has been devoted to overcoming drug resistance primarily
focusing on drug transport. A thoroughly investigated family of transporters that cause
increased efflux of drug with low specificity is the ATP-binding cassette (ABC)
transporter family, of which the P-gp pump is a member. There are drugs which shut
down the P-gp efflux pump and often these are used in combination with an anticancer
drug to act synergistically (Szakács et al. 2006; Peetla et al. 2013). Combinations of
multidrug – resistance gene silencers made up of siRNA or miRNA or with anticancer
drug have also been investigated (Peetla et al. 2013).
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There are several drugs that target epigenetic mechanisms currently in preclinical
or clinical trials or approved for use. Of particular interest is decitabine (DAC), which has
a molar mass of 228.21 g/mol and a molecular formula of C8H12N4O4 (Neupane, Y. R. et
al. 2015) . DAC is an analog to the nucleoside cytidine (shown in Figure 1a) and
therefore exploits the same metabolic pathway (Jordheim et al. 2013). It crosses the
membrane via the human equilibrium nucleoside transporter 1 (hENT1) protein
(Damaraju et al. 2012). Intracellularly, it is converted to its active form – DAC
triphosphate – then incorporates into the DNA during S-phase as shown in Figure 1b
(Jordheim et al. 2013). When DNMT attempts to methylate the daughter strand of DNA
in which the DAC has been incorporated in place of cytidine, DNMT is irreversibly
bound to DAC and degraded. Normally, a nucleophilic attack initiates DNMT’s
methylation of the substrate cytidine, methylation occurs, and the bond is broken by betaelimination at the carbon-5 atom. The nitrogen atom at position 5 of DAC causes an
unresolvable covalent bond to occur between DNMT and the carbon at position 6 of the
DAC. This triggers a DNA damage response and the DNMT is targeted for proteosomal
degradation (Stresemann and Lyko 2008; Yang et al. 2010). Initially, the result is
hemimethylated DNA as shown in Figure 1c. In subsequent round of replication the
DNMT remains depleted and the DNA becomes increasingly hypomethylated (Santini et
al. 2001). This hypomethylation of the DNA results in reactivation of silenced genes such
as tumor suppressor genes (Cramer et al. 2015).
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Figure 1: Molecular structure, metabolic pathway, and hypomethylation action of
decitabine (DAC). (a) The molecular structure of cytidine and DAC. The key difference is
the 5-carbon of cytidine being replaced by nitrogen in DAC. (b) DAC enters the cell
through the human equilibrium nucleoside transporter 1 (hENT1). It is subsequently
phosphorylated by deoxycytidine kinase, nucleoside monophosphate kinase, then nucleoside
diphosphate kinase to form DAC-triphosphate which is incorpoarated into DNA during Sphase. (c) Some deoxycytidylate-phosphate-deoxyguanylate (CpG) islands are methylated
(the addition of CH3 represented her by addition of a • to cytosine) in the initial DNA.
During normal replication, DNMT maintains methylation by addition of methyl groups to
the newly formed daughter strand symmetrically. In the presence of DAC, DNMT is
depleted leading to the DNA in the daughter cells being hemimethylated. Subsequent
rounds of DNA replication in the absence of DNMT will lead to increasingly
hypomethylated DNA. Figure 1a decitabine molecule is from (Fvasconcellos 2007).

At high doses, which are necessary to achieve therapeutic levels in solid tumors,
DAC is toxic, especially to the rapidly dividing cells in the bone marrow, and can cause
chronic myelosuppression and leukopenia. The mechanism of toxicity is DAC’s DNA
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damaging activity, replacing cytidine in the replicating cell, and not its hypomethylation
activity (Brown and Plumb 2004).
DAC has been successful in clinical trials against hematologic malignancies
(tumors that affect the blood, bone marrow, lymph, and lymphatic system). DAC is
approved for use in the treatment of myelodysplastic syndrome (MDS). It is also used
off-label to treat acute myeloid leukemia (AML) in the elderly and in a phase III trial.
But, the efficacy of DAC in treating solid tumors has been disappointing. This is due to
the difference in the pharmacokinetics and pharmacodynamics in between solid tumors
and hematological malignancies. In acidic conditions, DAC degrades due to cleavage of
the glycosidic bond. In basic and neutral aqueous conditions such as those in vitro
studies, the opening of the 5-azacytosine ring is the cause of the degradation (Stresemann
and Lyko 2008). In vivo, characteristics such as a very high clearance rate (half-life of
10-35 min), rapid degradation in acidic environment such as those in solid tumors (due to
cleavage of the glycosidic bond), and rapid degradation by cytidine deaminase (found
principally in the liver) come into play (Jabbour et al. 2008). Also, as DAC is S-phase
dependent, its efficacy in solid tumors could be affected by the slower dividing of cancer
cells in vivo versus in vitro (Momparler et al. 1997). It may take 5-15 days for all the cells
in a tumor to pass through S-phase (Brünner et al. 1989; Oloumi et al. 2010).

2.3 Lipid Biosynthesis in Drug Resistant Cells and Alteration with DAC
Altered lipid makeup of the cell membrane can be a characteristic of drug
resistant cells (Escribá et al. 2008). Recent studies have shown that in breast cancer drug
resistant cells (MCF-7/ADR) the lipid profile of the cell membrane is a mechanism of
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drug resistance and the lipid synthesis is epigenetically controlled (Peetla et al. 2010;
Vijayaraghavalu et al. 2012). The makeup of the membrane in these cells influences drug
transport or endocytosis for nanoparticle-mediated drug delivery. Peetla et al. compared a
breast cancer cell line with acquired resistance - MCF-7/ADR - to the sensitive breast
cancer cell line – MCF-7 (Peetla et al. 2010). The resistant cells had more sphingomyelin
(SM), phosphatidylinositol, cholesterol, and cholesterol esters leading to a more rigid,
compact, and hydrophobic membrane (Peetla et al. 2010). When anticancer drug
(doxorubicin) was added to the cells, it was seen that the greater hydrophobic makeup of
the resistant cell membrane led to sequestration of the drug in the membrane, therefore
less drug got into the cell. The intracellular concentration of anticancer agent required for
an antiproliferative effect was the same in resistant and sensitive cells (Peetla et al. 2010).
This supports the claim that it is the reduced uptake in the resistant cells that is a part of
the source of resistance. Membrane lipid alterations are known to occur concurrently with
most known drug-resistance mechanisms (Pallarés-Trujillo et al. 2000; Hendrich and
Michalak 2003).
The changes seen in the lipid profile of resistant cells could be due to numerous
influences, one of which could be hypermethylation of one or multiple genes implicated
in cell membrane protein/lipid synthesis (Vijayaraghavalu et al. 2012). The
sphingomyelinase (SMase) gene has been seen to be hypermethylated in 60% of breast
tumors. SMase hydrolyzes SM to become ceramide – a lipid with tumor suppression
functions and the ability to take the place of cholesterol in the cell membrane. Decreased
cholesterol in the membrane leads to greater fluidity. When treated with DAC, this
SMase gene is re-expressed (Demircan et al. 2009).
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Studies have shown that DAC treatment can reverse some of the changes in the
lipid composition and biophysical characteristics of the membrane of resistant cells,
causing an increase in drug sensitivity (Vijayaraghavalu et al. 2012; Peetla et al. 2013).
The lipid composition of the membrane of resistant cells treated with DAC displayed
increased SMase activity, thus decreasing the amount of SM in the membrane. SM,
cholesterol, and P-gp activity are interdependent (Slotte and Bierman 1988;
Vijayaraghavalu et al. 2012). Thus, P-gp expression was also seen to decrease and
fluidity of the membrane was increased. The biophysics and endocytic function of
resistant cells resembled that of the sensitive cells after DAC treatment and drug efficacy
was enhanced (Vijayaraghavalu et al. 2012; Peetla et al. 2013).

2.4 DAC-Nanogel
DAC has several characteristics that limit its use in vivo as discussed previously.
Hydrophilic drugs, such as DAC, can be loaded into hydrophilic nanogels at a higher
drug-loading capacity than other forms of drug delivery such as nanoparticles, polymeric
micelles, or liposomes. A nanogel is a nano-sized hydrogel (usually tens to hundreds of
nanometers in diameter) composed of hydrophilic polymer chains which are physically or
chemically cross-linked (Kabanov, A. V., & Vinogradov, S. V. 2009). It has been shown
that when DAC is loaded into a biodegradable N-isopropylacrylamide (NIPAM) based
nanogel its efficacy is increased compared to treatment with DAC alone in MCF-7/ADR
cells (Vijayaraghavalu and Labhasetwar 2013). This NIPAM –based nanogel has been
thoroughly studied for loading with DAC and the materials and methods used for the
synthesis, loading, and characterization of the DAC-nanogel have been optimized in
previous studies. The DAC is released from this nanogel due to biodegradation of the
12

nanogel. In the previous study, the DAC-nanogel diminished the transient nature of DAC
via more sustained DNMT1 depletion and prolonged cell cycle arrest in the G2/M phase.
The mechanism behind the sustained effect may be an increase in the stability of DAC
when it is loaded into the nanogel. This hypothesis is tested in the first aim of the
research herein. Instead of comparing the efficacy of DAC and DAC-nanogel as a
primary treatment, the second aim of the research herein compares DAC and DACnanogel as varying durations of pretreatments and calculates the effect by subsequent
response to antiproliferative drug treatment. Void (empty) nanogel was not used as a
control because it has shown no cytotoxicity in previous studies (Vijayaraghavalu and
Labhasetwar 2013). Another previous study – similar to the study showing that DAC
alone causes resistant cell’s lipid profile to resemble that of a sensitive cell – showed that
DAC-nanogel was even more effective than DAC alone in causing this change in the
lipid profile (Raghavan et al. 2015). The third aim of the research herein builds on the
previous research by again using DAC and DAC-nanogel but comparing their effects on
subsequent uptake of nanoparticles across the cell membrane.
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CHAPTER III
MATERIALS AND METHODS

3.1 Materials
N-isopropylacrylamide (NIPAM), n-hexane, benzene, vinyl pyrrolidone (VP),
sodium dodecylsulfate (SDS), sodium acrylate, N,N’-cystamine bisacrylamide,
ammonium persulfate (APS), maleic anhydride, dimethyl sulfoxide (DMSO), 5-aza-2’deoxycytidine (decitabine, DAC), Daidzin, and paclitaxel (PTX) were purchased from
Sigma–Aldrich Chemical Company (St. Louis, MO). Poly(ethylene glycol) (PEG, M.W.
~5000) was purchased from Polysciences, Inc. (Warrington, PA). Cell culture media,
Dulbecco’s phosphate-buffered saline (DPBS), penicillin and streptomycin were
purchased from the Central Cell Services Media Laboratory of the Lerner Research
Institute. MTS reagent was purchased from Promega (Madison, WI). Mouse plasma was
purchased from GeneTex Inc. (Irvine, CA).

3.2 DAC Solution
DAC (either 5 mg or 10 mg) was reconstituted to a concentration of 8.1 mg/mL
by addition of DMSO (maximum solubility of DAC in DMSO is 20 mg/mL) then kept at

14

-20 °C in 100 µL aliquots. The stability of storing these aliquots for up to four months
was confirmed through HPLC comparison with fresh stock. Upon use, the concentration
of DMSO was always diluted to below 0.1% v/v. DAC was protected from light
degradation in all experiments using aluminum foil or decreased lighting.

3.3 DAC Nanogel
3.3.1 Nanogel Synthesis
Nanogel was synthesized by surfactant polymerization of N-isopropylacrylamide
(NIPAM) (700 mg) in the presence of PEG-maleic anhydride polymer (PEGMA) (100
mg), using vinyl pyrrolidone (VP) (200 mg) as a co-monomer, sodium dodecylsulfate
(SDS) (200 mg) as a surfactant, ammonium persulfate (APS) (80 mg) as an initiator, and
N,N′-cystamine bis(acrylamide) (60 mg) as a S-S cross-linker, at 70 °C for six hours, as
previously described (Vijayaraghavalu and Labhasetwar 2013).

3.3.2 Loading Nanogel with DAC
Thirty mg of lyophilized nanogel was added to six mL MilliQ water in a 16 mL
glass vial (Fisher Scientific, Pittsburgh, PA) and stirred slowly at room temp until
dispersed. This was sonicated for five minutes at 20% amplitude using a Qsonica, LLC
(Newtown, CT) Q500 with a 1/8” microtip. This time and amplitude have been optimized
to achieve a low polydisperity index and to not create foam.
The dispersion was determined using a NICOMP™380 ZLS (Particle Sizing
Systems, Santa Barbara, CA) by dynamic light scattering at a scattering angle of 90 ⁰ at
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25 °C and zeta potential in the phase analysis mode and the current mode at a scattering
angle of −14 °.
Three hundred µL of the 8.1 mg/mL aliquots of DAC (aliquoted in DMSO) was
added in a dropwise fashion to the nanogel dispersed in water. This volume was with the
goal of obtaining an 8% wt/wt solution of the DAC weight to the nanogel weight which
has been determined to be optimal for loading. This was stirred for three hours in the cold
room at 4 °C.
Next, the dialysis tubing (MWCO 12-kD, Spectrum Laboratories, Rancho
Dominguez, CA) was prepared. The outside was wet to allow opening of the tubing.
Once open, MilliQ water was run through the tubing. The tubing was then soaked in
MilliQ water at a temperature of 85 - 90 °C for 30 min. This is done to remove the
sodium azide preservative that may remain from the manufacturing process.
The dialysis of the DAC-loaded nanogel was performed against MilliQ water for
30 minutes in the cold room. This amount of time was determined by previous work to be
sufficient to remove free DAC and DMSO. Next, the samples were frozen at -80 °C then
lyophilized over two days at −48 °C, 3.5 Pa, using FreeZone 4.5 (Labconco Corp.,
Kansas City, MO). The lyophilized samples were stored at -20 °C.

3.3.3 Determination of DAC Loading in Nanogel
To determine the loading of the nanogel, the DAC was extracted back out of a
small test sample. 2 mL MeOH was added to 1 mg of lyophilized DAC loaded nanogel in
a 8 mL glass vial (Fisher Scientific, Pittsburgh, PA) and stirred overnight (12 hours) at
100 rpm in the cold room at 4 °C. 1 mL of the solution was taken into a 1.5 mL
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Eppendorf tube and centrifuged at 14,000 rpm (Eppendorf 5417 R, Hauppauge, NY) for
10 min at 4 °C. DAC concentration in the supernatant was determined using HPLC
(Shimadzu Scientific Instruments, Inc., Columbia, MD).
A standard plot of DAC (0 - 50 µg/mL) was prepared using the same conditions.
Examples of standard curves from four different runs/days are shown in Figure 2. To be
sure of the extent of extraction, the above protocol for loading was followed except the
dialysis step was skipped so that all of the original DAC added to the nanogel should
remain. It was determined that recovery was over 99% which is also reported in another
study (Vijayaraghavalu and Labhasetwar 2013).

Figure 2: Standard HPLC curves of four different runs/days showing variability in area
under the curve and demonstrating the need to create a new standard curve each time a
loading concentration of DAC in nanogel is to be determined.

The HPLC conditions used to determine nanogel loading is described here. A C18
reversed phase column (Atlantis T3 –4.6 x 250 mm – 5 µm) was used with a mobile
phase consisting of sterile degassed methanol:water (60:40 v/v). The injection volume
was 25 µL. The flow rate was1.2 mL/min in isocratic mode for a total of six minute run
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time per injection. The UV detection wavelength was 228 nm (Vijayaraghavalu and
Labhasetwar 2013).

3.4 DAC Stability Analysis
3.4.1 Sample Preparation
Two mL mouse plasma samples (GeneTex Inc, Irvine, CA) in 8mL glass vials
(Fisher Scientific, Pittsburgh, PA) were warmed to 37 °C in a MaxQ Mini 4450 Benchtop
Incubated Orbital Shaker and kept rotating at 25 rpm. DAC solution, DAC-nanogel, or
void nanogel was added to the plasma to achieve the desired concentration as shown in
Table 1.
Sample

Concentration

DAC solution (high
concentration)

100 µg/mL

DAC solution (low
concentration)

300 ng/mL

DAC-nanogel

3 - 6 µg/mL

void nanogel

DAC-nanogel equivalent
mass/volume

Table 1: Sample concentrations are shown for a high DAC solution concentration (n = 2), a
low DAC solution concentration (n = 3), DAC-nanogel (n =4 ), and void (empty) nanogel (n
= 2). All samples are in mouse plasma.

The high and low concentrations of DAC solution provide a range within which
the DAC-nanogel stability curve can be compared to the DAC solution stability curve.
These concentrations are discussed further in section 4.2. A sample of 200 µL was taken
at timepoints 0, 1, 2, 4, and 8 hours and placed in cryovials and stored at -80 °C. Frozen
samples were lyophilized as above (section 3.3.2) for two days.
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3.4.2 Drug Extraction for Stability Curve Points
Before HPLC can be used to determine DAC concentration, the drug was
extracted from the samples. This method is similar to the method of drug extraction in
section 3.3.3 but instead of adding certain volume of methanol per weight, 200 µL
methanol was added to each lyophilized sample to obtain the same concentration as the
samples were previous to lyophilization. These were placed on an orbital shaker at 100
rpm in the cold room overnight. Next, the samples were vortexed vigorously and placed
in the centrifuge at 13,200 rpm for 10 min at 4 °C. The supernatant (~100 µL) was
collected in glass HPLC vials (Fisher Scientific, Pittsburgh, PA).
A liquid chromatography electrospray ionization tandem mass spectrometric
method was developed (LC/ESI/MS/MS) for quantification of DAC in plasma using
daidzin as internal standard. 20 µl of the sample (the supernatant from section 3.4.2) was
injected onto a Waters HPLC (2690 Separations Module, Waters, Corp., Franklin MA,
USA) and separated through a C18 column (2.1 x 150 mm, 5 µm, ODS, Phenomenex,
Torrance, CA) using a gradient starting from 95% mobile phase A (water containing 5
mM ammonium acetate) at flow rate of 0.2 ml/min for 2 min, to 100% mobile phase B
(acetonitrile containing 5 mM ammonium acetate) over 8 min and then with 100% B for
5 min as shown in Table 2.
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time (min)
0-2
2-10
10-15

Mobile Phase
5% B
5% B to 100% B
100% B

Table 2: Mobile phase timeline for binary method in HPLC analysis of plasma samples.

The HPLC column effluent was introduced onto a Micromass triple quadrupole mass
spectrometer (Quattro Ultima, Waters Inc., Beverly, MA) and analyzed using
electrospray ionization in positive mode with multiple reaction monitoring (MRM). A
potential difference of 3 keV was applied between the electrospray needle and the interior
of the ion source. Hot nitrogen gas (250 C) was used to help evaporating the solvent
from the charged droplets and argon was used as the collision gas. The MRM transitions
(m/z) were 457  113 for DAC and 417  255 for daidzin. The levels of decitabine in
plasma were calibrated using internal standard daiazin. The assay was linear over the
concentration range of 40 ng/mL -100 µg/mL. This method is adapted from published
work. (Xu et al. 2012). Note that the HPLC/UV/VIS method was used for determination
of loading and is described in section 3.3.3.

3.4.3 Stability Curves and Equations
The concentration data for the different timepoint samples of plasma were
normalized for easier comparison and interpretation as the initial concentration (the zero
hour timepoint) for each sample begins at 100% on the y-axis labeled ‘% DAC
remaining’. Graphs of both absolute concentrations and the normalized data are shown in
section 4.1.2. Normalization does not change the decay rate (K), just the Y0 value. The
data were fit to a one phase exponential decay model:
Equation 3.4:

𝑌 = (𝑌0 − 𝑌𝑚𝑖𝑛 )𝑒 −𝐾𝑡 + 𝑌𝑚𝑖𝑛
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where Y0 = the Y value when t (time) is zero, Ymin = the Y value at infinite time, and K is
the rate constant. The half-life was computed as ln(2)/K. A paired two-tailed t test was
also done to compute a p value and rule out the null hypothesis. The graph and
calculations were done using GraphPad Prism 5.

3.5 Cell Culture
MCF-7/ADR cells (a gift from Dr. U. S. Rao’s laboratory, Department of
Biochemistry and Molecular Biology, University of Nebraska Medical Center) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 15%
fetal bovine serum (Gibco BRL, Grand Island, NY) and 100 µg/mL penicillin and 100
µg/mL streptomycin in 75 cm2 culture flasks (BD Falcon, San Jose, CA). These
conditions were optimized for growth of these cells. Drug resistance was maintained by
culturing in media containing 100 ng/mL doxorubicin (Drug Source Co. LLC,
Westchester, IL) after every two passages.

3.6 MTS Assay and IC 50/IC70 Calculations
3.6.1 Sample Setup
MCF-7/ADR cells were seeded at a density of 1.5 x 104 cells/mL in six 96-well
plates (Lerner Research Institute, Cell Culture Services). Sixty wells per plate were
seeded (all except the edge wells which were filled with PBS to prevent evaporation)
with 100 µL media per well. After 24 hours cells were washed with PBS and treated with
normal media, DAC solution, or DAC-nanogel at a concentration of 50 ng of DAC per
mL of media. Three of the plates were incubated for 3 days at this stage (with normal
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media, DAC, or DAC-nanogel) and three of the plates were incubated for 5 days at this
stage (with normal media, DAC, or DAC-nanogel) as shown in Table 3.

Plate
number
1
2
3
4
5
6

Pretreatment (DAC concentration for
solution and nanogel is 50 ng/mL)
None (normal media) - 3 days
None (normal media) - 5 days
DAC solution - 3 days
DAC solution - 5 days
DAC-nanogel - 3 days
DAC-nanogel - 5 days

Table 3: Table showing setup for MTS assay. Each pretreatment type and duration is
shown. Note that plate #4 (pretreatment type DAC solution with a duration of 5 days) was
contaminated with fungus there are no results for this plate.

After the indicated pretreatment time (3 days or 5 days), cells were washed twice
with PBS and 100 µL paclitaxel (PTX) in media was added at concentrations ranging
from 0 – 20 µg/mL (0, 0.25, 0.50, 1, 2, 3, 4, 5, 10, and 20 µg/mL) and n = 6 for each
concentration of PTX. Paclitaxel incubation time was 3 days for all plates. After this,
cells were washed twice with PBS and normal media was added. After 2 days in normal
media, MTS assays were performed.

3.6.2 Cytotoxicity Assay
An aliquot of 20 µL MTS reagent was added to each well, the plates were
incubated for 2 hours at 37 °C, and color intensity was measured at 490 nm using a plate
reader (Bio-Tek Instruments, Inc., Winooski, VT).
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3.6.3 Dose Response Curves
Plate reader data was first transformed into logarithmic values then normalized so
that the average of the six (n = 6) of the PTX concentration zero of each plate is the 100%
growth point for that plate. Dose response curves were plotted on a semi-log graph.

3.6.4 IC50 and IC70 Calculations
To find the IC50/IC70 values for each treatment type, first a variable slope line was
fit to the data (already in log form) using this equation:

Equation 3.6

𝐴 −𝐴

1
2
𝑦 = 𝐴2 + 1+10log(𝑥
0 −𝑥)𝑝

Where y = % cell growth (normalized), A2 = % cell growth (normalized) at the bottom
plateau region of the curve, A1 = % growth at the top plateau region of the curve, x =
PTX concentration, x0 = the inflection point of the curve, and p = slope. To find the IC50,
y = 50. To find the IC70, y = 70.
Two-way ANOVA statistical analysis was calculated for IC50s and IC70s
comparing the no pretreatment to the DAC-nanogel treatments and determining if the
duration of pretreatment was the cause of the significance (which is aim 2). This
statistical analysis is discussed further in section 4.1.3 and detailed results from GraphPad
Prism are in Appendix B.
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3.7 Nanoparticle Uptake Study using Confocal Microscopy
3.7.1 Sample Preparation
MCF-7/ADR cells were seeded onto 35 mm glass bottom plates (MatTek Corp,
Ashland, MA) at a density of 1.8 x 104 cells/mL with 2.5 mL media in each plate. Cells
were allowed 24 hours to attach. After 24 hours, the cells were washed with PBS and
pretreatment of either media only, DAC in media (50 ng/mL), or DAC-nanogel in media
(50 ng/mL). The samples were left in the incubator with the pretreatment for 3 days after
which the cells were washed with PBS and normal media was added. Normal media was
changed every other day until 5 days post removal of pretreatment. At that time media
was removed and replaced with nanoparticles in media (200 µg of PLGA-based
nanoparticles in 2 mL of media) loaded with 6-coumarin dye loaded at 50 µg 6-coumarin
per 90 mg PLGA as previously described (Peetla et al. 2014). The nanoparticles in media
were added to the cells for 2 hours prior to confocal imaging. A lysotracker stain
(Lysotracker Red DND-99, Molecular Probes, Invitrogen, catalog number L7528) was
added to half the cell samples 30 minutes prior to imaging at a concentration of 75
ng/mL. The other half of the cell samples were treated with a membrane dye (Cell Mask
Deep Red Plasma Membrane Stain, Invitrogen, catalog number C10046) five minutes
prior to imaging at a concentration of 5 µg/mL. Immediately before imaging, cells were
washed twice with PBS to remove excess nanoparticles and dyes and phenol red free
media with DAPI was applied for imaging.
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3.7.2 Confocal Microscopy
Live cell imaging was performed using a spinning disk confocal microscope
(Ultraview Vox, PerkinElmer, Waltham, MA). Images were captured using alternating
illumination with lasers for capturing nanoparticle (6-coumarin) signal (green filter, Ex λ
488) and dye signals for the lysotracker (red filter, Ex λ 561) and cell membrane (deep
red filter, Ex λ 640). Stacks of images were taken for each sample in the z-plane.
Distance between each ‘slice’ of a stack is 0.50 µm. Images shown from confocal are
single slices for clarity. Magnification for all images was 63X. All images were
brightened 50% and sharpened 50% for viewing in print. Image enhancements and
processing was done using Image-Pro.

3.7.3 Quantification of Nanoparticle Uptake
Quantification of nanoparticle uptake was done using Excel and Image-Pro. For
each cell sample, a stack of images was captured encompassing the entire cell monolayer.
Cell monolayers were approximately 11 – 12 µm thick. Images (‘slices’) were taken 0.5
µm apart, therefore a stack of about 20 images was captured for each cell sample. Five
slices, 0.50 µm apart, taken from the middle of each stack was analyzed for the
nanoparticles uptake quantification. For each slice, the total intensity of green in the
image was determined using Image-Pro. Number of cells in the image was counted in
Image-Pro, and the average (of the 5 slices) intensity per cell was calculated in Excel for
that sample. There was only one replicate per data point (the slices were of the same
sample and many of the cells spanned multiple slices) so there are no statistical
calculations shown with this data.
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CHAPTER IV
RESULTS AND DISCUSSION

4.1 Results
4.1.1 DAC-nanogel Characterization and Loading
All of the aims include the use of DAC-nanogel. The physical characteristics of
the synthesized nanogel before and after loading with DAC are shown in Table 4.
Formulation
Void nanogel
DAC-nanogel

Efficiency of loading (%) Loading (%) Mean diameter (nm)
209.0
80.52
6.1
227.1

PI
0.05
0.05

Zeta potential (mV)
-21.55
-19.90

Table 4: Physical characterization of nanogel before (void nanogel) and after (DACnanogel) DAC loading. The efficiency of loading refers to the percentage of DAC that was
encapsulated out of the entire amount of DAC added to the nanogel. The loading is the
weight by weight percentage of DAC to total weight (DAC and nanogel). This data
represents one synthesized batch of void nanogel and one batch of loaded nanogel. Refer to
the explanation in section 4.1.1 for further information on the samples . PI, polydisperity
index.

The mean hydrodynamic diameter, polydisperity index (PI), and zeta potential were
determined using a particle sizer as described in section 3.3.1. The void nanogel and
DAC-nanogel had a mean diameter of 209.0 nm and 227.1 nm, and zeta potentials of 21.55 mV and -19.90 mV, respectively. Both had a PI of 0.05. This PI is consistent with
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previous nanogel batches used in published studies and is less than the general guideline
of 0.1 to show uniformity of the sample. The efficiency of loading (amount of DAC
inside the nanogel versus total DAC added to the nanogel suspension) for the DACnanogel was 80.52 %. The loading (percent weight of DAC to the total – DAC plus
nanogel - weight) was 6.1 %. The data in Table 4 represents one batch of synthesized
void nanogel and one batch of DAC loaded nanogel. There are the mean diameter, PI,
and zeta potential values for three aliquots of the void nanogel included in the values for
void nanogel and six aliquots included in these values for DAC-nanogel included in
Table 4. The efficiency of loading and loading (by mass) values are n = 1 since one
batch of DAC-nanogel was prepared and put into aliquots. Then, one of those aliquots
was used for DAC –nanogel loading determination using HPLC-UV/VIS, See section 4.2
for more information on the data used in Table 4.

Figure 3: Hydrodynamic diameter and particle size distribution of a void nanogel (a) and
DAC-nanogel (b). The mean diameter of the void nanogel shown here is 219.6 nm and the
PI is 0.06. The mean diameter of the DAC-nanogel shown here is 223.0 nm and the PI is
0.04.
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Representative chromatograms of DAC and DAC-nanogel (after DAC extraction) are
shown in Figure 4.

Figure 4: Representative chromatograms from the HPLC-UV/VIS analysis of DAC and
DAC-nanogel. Area under the curves is representative of mass. Max intensity listed in the
upper right hand corner of each chromatogram as well as the scale on the vertical axis
(mAU, milliAbsorbance Units) gives an indication of peak size. (a) Methanol used as blank.
Methanol is used for the drug extraction. A small peak of residual DAC can be seen at the
approximately 2.5 minute mark. (b) DAC in solution. Note the double peak indicating
isomers as discussed below in section 4.2. (c) DAC-nanogel after extraction of the DAC by
stirring in methanol overnight and centrifugation.

4.1.2 DAC Stability
The objective of this experiment is to see the stability of DAC Solution (alone)
versus DAC-nanogel in mouse plasma (GeneTex Inc. Irvine, CA) at physiological
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conditions. The DAC or DAC-nanogel was added to mouse plasma warmed to 37 ⁰C.
Samples were taken at time intervals to observe the stability of the DAC alone versus
DAC-nanogel over time.
Figure 5a compares DAC solution with a high concentration (100 µg/mL) to the
DAC solution with a low concentration (300 ng/mL) before normalization. The rate
constants (K) are 1.069 for the high initial concentration and 1.075 for the low initial
concentration. Figure 5b compares the same data except it is after normalization so that
the first timepoint (t = 0) taken is adjusted to be 100% on the ‘% DAC remaining’ axis on
the graph. The rate constants (K) are 1.073 for the high initial concentration and 1.071 for
the low initial concentration. The differences in the rate constants (K) are due to
differences in rounding during curve calculations in GraphPad Prism between the
absolute data and the normalized data. The curves shown are model curves – one phase
exponential decay – in all cases.
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(a)

(b)

Figure 5: Stability curves of a high initial DAC concentration (100 µg/mL) (n = 2) in plasma
and a relativley low initial DAC concentration (300 ng/mL) (n = 3) in plasma. (a) Absolute
concentration values are shown using a segmented y-axis. Error bars designate s.e.m. (b)
This data is the same data as in (a) except it is normalized to begin at 100%. Error bars
designating s.e.m are included for all points but cannot be seen in (a) and can be seen at
only a few points in (b) due to the y-axis constraints and the relatively small values of the
s.e.m. data. These high and low concentration curves are combined to form ‘DAC solution’
in Figure 6.

The data for the two DAC solution curves is combined and normalized to form
‘DAC solution’ in Figure 6. The resulting curves and rate constants (K) are shown and
the main focus is that the concentration of DAC in DAC-nanogel is decreasing slower
than DAC alone.
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Figure 6: Stability in mouse plasma at physiological conditions. n = 5 for DAC Solution,
n = 4 for DAC-nanogel measured using HPLC-MS/MS. Error bars designating s.e.m. are
within symbols for certain data points because of the relatively small value of s.e.m. for
those points compared to the y-axis . p = 0.033 DAC solution vs. DAC-nanogel.

4.1.3 Duration of Pretreatment
MCF-7/ADR cells were pretreated with DAC solution, DAC-nanogel, or no
pretreatment for three or five days. The dose response curve is a measure of their
response to subsequent addition of paclitaxel (PTX).
Figures 7 – 9 show that DAC-nanogel pretreatment for a duration of 5 days has
an effect on subsequent drug antiproliferative effect significantly greater than the effect
of DAC-nanogel pretreatment for a duration of 3 days. The effect occurs at lower
concentrations of PTX as shown in Figure 7. This could be due to a threshold effect
discussed further in section 4.2.
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Figure 7: Dose response curves for the different pretreatment types and durations. All
samples are normalized with the zero concentration being 100% growth. Three data points
in the ‘5 day DAC Nanogel’ group are excluded from the line and IC50/IC70 calculations as
discussed in the text. n = 6.

Two-way ANOVA statistical analysis was performed to determine whether a
duration of 5 days of pretreatment with DAC-nanogel is significantly more effective than
a duration of 3 days of pretreatment with DAC-nanogel on the efficacy of PTX as
outlined in aim two in section 1.3. The dose response curves are shown separately for
3 day pretreatment and 5 day pretreatment in Figure 8.
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Figure 8: Dose response curves for the different pretreatment types and durations showing
(a) 3 day no pretreatment and DAC nanogel pretreatment and (b) 5 day no pretreatment
and DAC nanogel pretreatment. All samples are normalized with the zero concentration
being 100% growth. Three data points in the ‘5 day DAC Nanogel’ group are excluded
from the line and IC50/IC70 calculations as discussed in the text. n = 6.

The variable slope lines fit to each set of data to calculate IC50 and IC70 values are
in Appendix A. The IC50/IC70 results are shown in Figure 9.
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Figure 9: IC50 and IC70 concentrations. This figure shows the effect of durations of 3 days
and 5 days of DAC-nanogel pretreatment on efficacy of subsequent PTX treatment as
described in aim two. For the IC50s, the effect of duration on DAC-nanogel pretreatment is
not significant. For the IC70s, p = 0.0019 for the significance of the duration of DAC-nanogel
pretreatment. The difference in the ‘None’ pretreatment time is used as a control for the
difference in the DAC-nanogel pretreatment type. Further explanation of the two-way
ANOVA analysis used to find the significance is described in the text in this section. n = 6
for all. Three data points in the ‘5 day DAC Nanogel’ group are excluded from the IC50/IC70
calculations as discussed in the text.

The IC50 (concentration of the drug which causes 50% of the maximum inhibition
of cell viability) for the 3-day incubation with no pretreatment and DAC-nanogel
pretreatments are 43.17 ± 1.11 and 11.33 ± 1.03 µg/mL respectively, and 5-day
incubation with no pretreatment and DAC-nanogel pretreatments are 30.52 ± 1.04 and
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11.61 ± 1.20 µg/mL respectively. The IC70s (concentration of the drug which causes 70%
of the maximum inhibition of cell viability) for the 3-day incubation with no pretreatment
and DAC-nanogel pretreatments are 20.73 ± 1.06 and 6.01 ± 1.03 µg/mL respectively,
and 5-day incubation with no pretreatment and DAC-nanogel pretreatments are 16.68 ±
1.02 and 2.36 ± 1.18 µg/mL, respectively.
The two-way ANOVA analyzes how the IC50/IC70 concentrations are influenced by two
factors – pretreatment type (none or DAC-nanogel) and duration (3 or 5 days). There is a
difference in the ‘none’ pretreatment type between the 3-day and 5-day for both the IC50
and IC70 concentrations as can be seen in Figure 9. This difference - due to some factor
associated with the two day difference in incubation time – affects the antiproliferative
effect of the subsequent PTX treatment. This difference (in the no pretreatment group)
must serve as a control for the DAC-nanogel pretreatment group. Two-way ANOVA
accomplishes this by analyzing whether there is a combination effect of interaction
between the duration and the pretreatment type and what the significance of of each of
them (duration and pretreatment type) alone is on the results (IC50/IC70). The DAC
solution was not used for any statistical analysis since there is not a 5-day sample.
Reports from GraphPad Prism with two-way ANOVA results are shown in Appendix B.
The two-way ANOVA results concluded that for the IC50 data, a difference between the
3-day and 5-day DAC-nanogel cannot be considered significant because of the difference
also seen between the 3-day and 5-day no pretreatment samples. The two-way ANOVA
results concluded that for the IC70 data, a difference between the 3-day and 5-day DACnanogel can be considered significant because it is significantly larger than the difference
between the 3-day and 5-day no pretreatment samples. This type of comparison is
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examining the ratio of a ratio and then determining whether the difference is significant.
The significance of the effect of 5-day DAC-nanogel pretreatment (compared to 3-day
DAC-nanogel pretreatment) is p = 0.0019. This is the effect of a longer duration with
DAC-nanogel which is aim 2 of the research herein.
Note that the DAC solution pretreatment for five days sample was contaminated
and is not included in Figures 7 - 9. The DAC-nanogel 5 days sample has three data
points that indicate an increase in cell proliferation despite increased concentrations of
PTX which isn’t possibly correct. Those three points are designated by red arrows in the
graph but the dose-response curve does not incorporate them and they are not included in
IC50 or IC70 calculations.

4.1.4 Uptake of Nanoparticles
Confocal images in Figure 10 – Figure 13 show MCF-7/ADR cells with one of
three pretreatment types (none, DAC Solution, or DAC Nanogel) and with one of two
dyes - Lysotracker, or ‘Membrane Stain’ (also known as Cell Mask). The Lysotracker
appears red in color and stains acidic organelles. The membrane stain appears ‘deep red’
or purple and stains the plasma membrane. The green color is the nanoparticles loaded
with 6-coumarin fluorescent dye. The blue is the cell nuclei dyed with DAPI. Although
some cells look larger than others (see Figure 10 and Figure 11), all images are at 63
times magnification. The different size of the nuclei and cells may be due to the degree of
confluency in the plate. It can also be seen that the sample with no pretreatment and
lysotracker stain looks redder whereas the DAC Solution pretreatment and the DAC
Nanogel pretreatment have an orange color. This is due to the amount of green 636

coumarin nanoparticles that were taken up by the pretreated cells. This can be confirmed
by looking at Figure 12 and noting that when the colors are separated the Lysotracker red
looks just as red in all the samples. In Figure 12, the Lysotracker stain reveals that the
nanoparticles are not trapped in intracellular vesicles such as lysosomes since the green
can be seen throughout the cytoplasm and is not just appearing in the same location as the
lysotracker stain. In Figure 13, although it can be difficult to see the green color in the
image, there is some green fluorescence appearing in the No Pretreatment sample. The
intent of using a membrane stain was to be able to visualize endocytosis of the
nanoparticles by correlating endocytic rate with a decreased signal from the membrane
stain (due to stained lipids being endocytosed). In the images in Figure 13, the greatest
intensity of membrane dye appears in the DAC Nanogel pretreatment group. This could
mean that it has the lowest rate of endocytosis (assuming the intensity of membrane stain
signal is inversely correlated to nanoparticle uptake) but that would not corroborate the
fact that it has the second highest amount of nanoparticle uptake (according to quantified
results of 6-coumarin loaded nanoparticle uptake shown in Figure 14). The lowest
intensity of membrane stain appears to be in the DAC Solution, indicating that it has the
highest rate of endocytosis. The highest rate of endocytosis appearing in the DAC
solution sample does collaborate with the uptake in nanoparticles being the greatest for
this sample as shown in Figure 14. The membrane stain did not serve to (inversely)
correlate with endocytic rate as evidenced by comparing the signal intensity of the
membrane stain in each of the three samples to the quantified uptake results in Figure 14.
A case for the membrane stain intensity serving as an indicator of endocytic rate could be
performed as a proof of concept study as mentioned in section 5.2. The membrane dye
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may be useful as a confirmation that the nanoparticles are inside the cells, especially
when the images can be seen in 3D, but was not useful in this study. However, the
samples that received the membrane dye can still be used for nanoparticle uptake
quantification shown in Figure 14.
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Figure 7: dfgdfgdfgdfgdfgfddfg?
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Figure 8: sdfsdfsdf
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Figure 9
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Figure 12: sdgoifisjdf

Figure 10
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The intensity of the green fluorescence was quantified for each sample (no
pretreatment, DAC solution pretreatment, and DAC nanogel pretreatment) from the
confocal images is shown in Figure 14.

Figure 14: Quantification of nanoparticles loaded with 6-coumarin (green) intensity in
MCF-7/ADR cells. Each bar represents one sample, n = 1 (although the total green intensity
of each image was divided by the number of cells in that image, the green intensity inside
any individual cell was not determined for this study). * Note that the bar for the
Membrane stain - no pretreatment sample is not zero, it is 81.

The total intensity of the green (indicating nanoparticles) in each image was divided by
the number of cells in that image to account for the different numbers of cells between
images. For both stains, the graph shows that the DAC solution pretreatment caused the
greatest increase in nanoparticle uptake and the DAC nanogel pretreatment caused an
increase as well, although not as large. For the Lysotracker stain group, the DAC solution
increases uptake by 27 times, and DAC nanogel increases uptake 9 times over the
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control. In the cell membrane stain group, the DAC solution increases uptake by 421
times, and DAC nanogel increases uptake 141 times over the control. The reason for the
discrepancy in green fluorescence / nanoparticle uptake between the two dyes is not clear.
Since the overall uptake is lower in the cells treated with the cell membrane stain, it could
be that the stain is interfering with endocytosis of the nanoparticles. It is not the case that
the membrane stain color is interfering with the resulting green intensity. The confocal
microscopy prevents this from happening by capturing the different colors independently
and consecutively (not all in one image at one time).

4.2 Discussion
The physical characterization of the nanogel before and after DAC loading is
comparable to previous research performed by Vijayaraghavalu and Labhasetwar (2013)
from which the method of nanogel synthesis, loading, and loading determination was
adapted. The loading (and loading efficiency) was within the s.e.m. of the previous
research (the DAC-nanogel loading and loading efficiency from the previous research
was 80 ± 5 % and 6.4 ± 0.4 %, respectively, and 80.52 % and 6.1 %, respectively for this
study herein). The loading of the nanogel was determined using HPLC-UV/VIS
according to the method in previous research by Vijayaraghavalu and Labhasetwar
(2013). The chromatograms shown in Figure 4 show that DAC can have a double peak
which is not entirely separated but there are two apexes. This was confirmed by mass
spectrometry during the DAC in plasma stability study to be two isomers of DAC.
Therefore, total area under both peaks is included for the DAC analysis.
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The mean diameter, PI, and zeta potential values are determined to assess
continuity between batches so that experimental results can be considered comparable.
Mean diameter of the void nanogel and DAC-nanogel was larger in this study (the void
nanogel and DAC-nanogel mean diameter from the previous research was 233 nm and
244 nm, respectively, and 209.0 nm and 227.1 nm, respectively for this study herein). It
is unknown whether the difference in mean diameter is significant since there is not a
value given for the s.e.m. for the previous research.
Polydisperity index (PI) was lower in this study (the void nanogel and DACnanogel PI from the previous research was 0.06 and 0.11, respectively, and 0.05 and 0.05,
respectively for this study herein). The sonication step was optimized for this study to
achieve a low PI and not create foam as outlined in section 3.3.2. A PI less than 0.1 which was the case for all samples in this study - is a general guideline that indicates
uniformity of the sample. Particle size distribution around the mean diameter can be
observed by the distribution graph from the dynamic light scattering as shown in
Figure 3. The distribution of the nanogels is similar to the distribution shown in the
previous research by Vijayaraghavalu and Labhasetwar (2013), as would be predicted
based on the values for the mean diameter and the polydisperity index also being similar.
The PI also serves as a confirmation that the sonication has successfully dispersed the
nanogel.
The zeta potential was within the s.e.m. from the previous research (the void
nanogel and DAC-nanogel zeta potential from the previous research was -25 ± 4.0 mV
and -19 ± 1.0 mV, respectively, and -21.55 mV and -19.90 mV, respectively for this
study herein). The zeta potential is related to the electrical surface potential of the
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nanogel (but not the same as particle charge). It is a measure of the electrical potential
difference at the location of the slipping plane and is a key indicator of stability of a
colloidal dispersion. It was used in this study as another means of comparison of the
current nanogel with previous research to assess whether the different nanogel batches
are comparable. The results from the DAC stability analysis verify that increased stability
of DAC in nanogel could be a reason for the greater efficacy seen when using DACnanogel rather than DAC solution in previous studies (Vijayaraghavalu and Labhasetwar
2013; Raghavan et al. 2015). A high and a low concentration of DAC solution provide a
range within which to compare the stability curve to DAC-nanogel as suggested in the
American Association of Pharmaceutical Scientists Journal (van de Merbel et al. 2014).
A concentration of 50 ng/mL DAC (the concentration used as pretreatment in the
IC50/IC70 and confocal experiments) as the beginning concentration would not have
produced a detectable stability curve because the lower limit of quantification (LLOQ)
for the HPLC - mass spectrometry method was 40 ng/mL DAC. The concentration of
100 µg/mL was chosen while optimizing the protocol to be high enough that a stability
curve could be observed. Patient data showing 300 ng/mL (1 µM DAC is equal to 228
ng/mL) to be a clinically relevant concentration (Karahoca and Momparler 2013). The
DAC-nanogel did not reach a plateau during the experiment. This is reflected in the value
of Ymin which is extrapolated out and found to be 9.27, which is past the time of the last
sample taken at 8 hours. The absolute values or kinetics from this stability study are not
relevant in vivo as there are many more factors in play in animal models/clinical studies
such as renal clearance and drug metabolism. But as a mechanistic and comparative study
it is useful in developing new theories and experiments that could lead to in vivo or
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clinical studies. The increased stability of the DAC in nanogel (half- lives of the DAC
and the DAC in nanogel were 39 minutes and 2 hours 12 minutes, respectively) also
provides a mechanism by which a longer duration of the DAC-nanogel pretreatment is
leading to greater efficacy of the subsequent anticancer drug as shown in the IC50 and
IC70 values in Figure 9.
The dose response curves and IC70 values correlate with the stability data by
supporting the hypothesis that DAC is more stable in nanogel by showing that the DACnanogel 5-day pretreatment has the greatest effect on subsequent drug efficacy. However,
the effect is not seen at high concentrations of PTX. This could be because at these very
high concentrations, enough PTX is intracellular that the efficacy is the same for the
pretreated samples. It has been shown in a previous study that this can be the case where
there is a threshold affect (Peetla et al. 2010). Doxorubicin is a preferred drug for treating
breast cancer but PTX is rather a broader spectrum anticancer drug used for treating
different types of cancers.
The confocal experiment showed that the greatest increase in nanoparticle uptake
occurred in the DAC solution pretreated cells, not DAC-nanogel pretreated as was
hypothesized. It could be that if more time had elapsed since pretreatment with DAC then
the DAC-nanogel would have had the greater effect on uptake. The protocol for the
confocal experiment requires 3 days of incubation with pretreatment, then the confocal
and nanoparticle addition is performed 5 days after the removal of the pretreatment. One
study in particular has shown that timing of the experiment could impact whether the
DAC solution of DAC-nanogel seem to be having a greater impact (Vijayaraghavalu and
Labhasetwar 2013). In that study, DAC solution has a more pronounced affect at an
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earlier timepoint with regards to antiproliferative effect (of the DAC/DAC-nanogel
itself), DNMT1 depletion, and cell cycle arrest. But then at later timepoints in all these
aspects, the sustained effect of DAC-nanogel reverses the earlier trend in drug resistant
cells. Although in that study, the measured responses are not nanoparticle uptake or
perhaps membrane lipid alterations, the sustained effect that DAC-nanogel confers may
be applicable to understanding the DAC solution efficacy at one timepoint for the
confocal data. There are not any timepoints from that previous study that exactly match
the pretreatment duration and post-treatment time of the confocal experiment for a more
direct comparison. Previous study showing that DAC-nanogel caused a greater decrease
in cholesterol-SM rafts than DAC solution and this phenomenon increased from one day
post DAC or DAC-nanogel treatment to 5 days and 8 days post treatment (Raghavan et
al. 2015). Since the rafts confer greater rigidity, DAC-nanogel pretreatment would
increase fluidity and thereby should have a greater uptake of nanoparticles than the
solution treated group. Accordingly, the nanoparticle uptake should have been greater in
DAC-nanogel treated cells than in DAC solution treated cells. However, in the previous
study where lipid changes were analyzed, the medium was changed and hence DAC
remained in the culture medium whereas for confocal microscopy study the medium was
replaced after 3 days. Even though the DAC solution had a greater effect, the DACnanogel effect was still 9 and 141 – fold higher (for lysotracker and membrane stain,
respectively) than the control and DAC-nanogel confers benefits over DAC solution in
vivo as outlined previously.
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CHAPTER V
CONCLUSIONS AND RECOMMENDATIONS

5.1 Conclusions

All experiments proved some benefit of DAC and/or DAC-nanogel pretreatment
to overcome drug resistance. The stability of DAC in nanogel was proven to be greater
than DAC alone (the half-lives were 2 hours 12 minutes and 39 minutes, respectively) in
mouse plasma under physiological conditions using HPLC/MS. The effect of different
durations of pretreatment on subsequent anticancer drug efficacy in MCF-7/ADR cells
was found using MTS assays. The results show that DAC-nanogel pretreatment for a
duration of 5-days causes the greatest increase in efficacy. At the higher doses all
pretreatments have a similar response. This is why both IC50 and IC70 were calculated for
further comparison of the data. IC50s of pretreated cells were lower than cells without
pretreatment, but there was no significant difference between DAC solution and DACnanogel at 3 days. IC70 showed a significant difference for the DAC-nanogel 5-day
pretreatment sample compared to the DAC-nanogel 3-day sample and accounting for the
difference seen in the control (no pretreatment) sample. The effect of DAC and DAC-
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nanogel pretreatment on the subsequent uptake of nanoparticles in drug resistant breast
cancer cells was visualized using confocal microscopy and the uptake of nanoparticles
was quantified using the green intensity per cell. At 5 days following a 3-day
pretreatment, the confocal data showed that DAC solution had the greatest increase in
uptake of nanoparticles (27 and 421 fold increases with respect to untreated cells)
followed by DAC-nanogel (9 and 141 fold increases with respect to untreated cells). The
images showed that nanoparticles are not trapped in intracellular vesicles based on the
green nanoparticles being seen throughout the cytoplasm, not preferentially overlapping
with the red lysosome stain.

5.2 Recommendations

1. There are benefits of nanogel that have been postulated but have yet to be verified.
For instance, nanogel may protect DAC from cytidine deaminase in the liver
and/or decreases bone marrow toxicity by causing less DAC to pass into the bone
marrow.
2. It would be interesting to see what the stability of DAC versus DAC-nanogel looks
like when carried out in liver tissue (instead of plasma) under physiological
conditions.
3. The polyethylene glycol (PEG) on the nanogel surface should cause an increase in
circulation time and cause more accumulation at the tumor site passively via the
enhanced permeability (EPR) effect. This hypothesis could be tested.
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4. Nanogel surfaces could be made with actively targeting ligands for increased tumor
accumulation.
5. Perform a proof of concept study for corroborating deep red plasma stain
(membrane dye) with endocytotic rate using cells with varying known endocytotic
rates.
6. DAC crosses the membrane via human equilibrative nucleoside transporter 1
(hENT1). It has been proposed that the increased efficacy of DAC-nanogel could be
due to the nanogel crossing the membrane via an endocytic mechanism instead of
hENT1. This different mode of membrane transportation could affect the
conversion rate of intracellular DAC into its active form - DAC-triphospate – which
is incorporated into the DNA (Vijayaraghavalu and Labhasetwar 2013). Whether or
not DAC-nanogel enters the cell via hENT1 could be studied using a hENT1
specific inhibitor such as S-(4-nitrobenzyl)-6-thioinosine (NBTI) on cells. These
hENT1 deficient cells could then be treated with DAC-nanogel. The amount of
intracellular DAC in these hENT1 deficient cells could then be directly quantified
using a HPLC-MS/MS method such as the one described in this paper. If hENT1
inhibition does not cause a change in intracellular DAC this would indicate that
DAC-nanogel crosses the membrane differently than DAC and vice versa.
7. A HPLC-MS/MS method for quantifying intracellular DAC-triphosphate has been
developed and validated (Wang et al. 2013). This could be used to determine if the
conversion rate of DAC to its active form – DAC-triphosphate – differs between
DAC-nanogel and DAC treatment.
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8. The confocal data quantifying the uptake of nanoparticles is n = 1. The same
experiment could be carried out but with more replicates (n = 3 or greater).
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APPENDIX A

Nonlinear fit curves for IC50 and IC70 calculations from section 4.1.3.
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APPENDIX B
Two-way ANOVA results from GraphPad Prism.
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